Johns Hopkins Dermatology Expands Advanced Care for Inflammatory and Autoimmune Skin Conditions with Addition of XTRAC® Excimer Laser

Rhea-AI Summary

Johns Hopkins Dermatology added the XTRAC 308 nm excimer laser to its clinical offerings on Feb 18, 2026, expanding targeted treatment options for psoriasis, vitiligo, atopic dermatitis, and other complex inflammatory skin diseases.

The device will support patient care and ongoing clinical research at Johns Hopkins and reinforces STRATA Skin Sciences' (Nasdaq: SSKN) collaboration with leading academic centers.

Market Reaction

-13.22% $0.17

15m delay 35 alerts

-13.22% Since News

-24.3% Trough in 16 min

$0.17 Last Price

$0.13 $0.28 Day Range

-$170K Valuation Impact

$1M Market Cap

0.2x Rel. Volume

Following this news, SSKN has declined 13.22%, reflecting a significant negative market reaction. Argus tracked a trough of -24.3% from its starting point during tracking. Our momentum scanner has triggered 35 alerts so far, indicating elevated trading interest and price volatility. The stock is currently trading at $0.17. This price movement has removed approximately $170K from the company's valuation.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.

Key Figures

Excimer wavelength: 308 nm Supporting studies: more than 300 published peer-reviewed clinical studies

2 metrics

Excimer wavelength 308 nm XTRAC excimer laser wavelength used in dermatologic treatments

Supporting studies more than 300 published peer-reviewed clinical studies Clinical evidence base for excimer laser treatment procedures

Market Reality Check

Price: $0.3163 Vol: Volume 5,164,313 is 5.28x...

high vol

$0.3163 Last Close

Volume Volume 5,164,313 is 5.28x the 20-day average of 978,102, indicating heavy trading ahead of this news. high

Technical Shares at $0.3163 are trading below the 200-day MA of $1.82 and sit far beneath the $3.86 52-week high.

Peers on Argus

SSKN traded down 8.32% while peers were mixed: BMRA scanner flag showed an up mo...

1 Up 1 Down

SSKN traded down 8.32% while peers were mixed: BMRA scanner flag showed an up move of 3.95%, and TNON moved down 5.28%. Broader Medical Devices peers such as RSLS (+29.8%) and LFWD (+3.72%) rose, highlighting a stock-specific decline for SSKN.

Historical Context

5 past events · Latest: Feb 17 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Feb 17	Clinical efficacy data	Positive	-8.3%	Meta-analysis showed strong PASI improvements with 308 nm excimer therapy.
Dec 09	Commercial expansion	Positive	+6.5%	Showcased XTRAC and TheraclearX and reported early adoption momentum in Mexico.
Nov 13	Q3 2025 earnings	Negative	-9.5%	Reported revenue decline and net loss despite some improvement in EPS and recurring revenue.
Nov 06	Reimbursement update	Positive	-4.7%	CMS confirmed coverage and future CPT descriptor expansion for excimer laser codes.
Nov 05	Earnings scheduling	Neutral	+0.0%	Announced date and details for the upcoming Q3 2025 earnings call.

Pattern Detected

Recent history shows SSKN often declined after generally positive XTRAC and reimbursement news, while mixed financial results and neutral scheduling updates were met with aligned or mildly negative reactions.

Recent Company History

Over the last few months, SSKN has focused on its XTRAC excimer laser franchise and reimbursement positioning. On Nov 5, 2025, it scheduled its Q3 call, followed by Q3 results on Nov 13, 2025 with $6.9M revenue and an improved EPS of -$0.36. A Nov 6, 2025 CMS decision expanded future excimer laser CPT coverage, and a Dec 9, 2025 update highlighted international XTRAC and TheraclearX adoption. On Feb 17, 2026, a meta-analysis confirmed XTRAC efficacy. Today’s Johns Hopkins placement continues that clinical-validation and adoption theme.

Market Pulse Summary

The stock is dropping -13.2% following this news. A negative reaction despite the Johns Hopkins XTRA...

Analysis

The stock is dropping -13.2% following this news. A negative reaction despite the Johns Hopkins XTRAC placement fits a pattern where positive clinical or reimbursement news did not consistently support the share price, as seen after prior XTRAC efficacy and CMS updates. With the stock at $0.3163, well below the $3.86 52-week high and facing an announced Nasdaq delisting effective around February 19, 2026, regulatory and listing risks may have outweighed this incremental commercial win.

Key Terms

excimer laser, phototherapy, autoimmune, peer-reviewed, +1 more

5 terms

excimer laser medical

"Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment"

An excimer laser is a high-energy, pulsed ultraviolet light device that removes or reshapes tiny amounts of material with extreme precision, like a scalpel made of light. Investors watch it because it underpins key businesses—such as corrective eye surgery and semiconductor manufacturing—so demand, regulatory approval, maintenance cycles, and technological upgrades for excimer lasers can meaningfully affect revenue, margins, and competitive positioning of companies that make or use them.

phototherapy medical

"expanding access to targeted, FDA-cleared phototherapy in these prestigious centers"

Phototherapy is a medical treatment that uses specific wavelengths of light to change biological processes in the body—like easing newborn jaundice, treating skin conditions, or improving mood in seasonal depression. Investors care because demand, regulatory approvals, device makers, and reimbursement rules determine how broadly the therapy is adopted; successful clinical results or new, easier-to-use devices can create business growth similar to a new tool that suddenly makes a common job faster and cheaper.

autoimmune medical

"inflammatory and autoimmune skin diseases, including psoriasis, vitiligo"

An autoimmune condition is when the body’s natural defense system mistakenly attacks healthy tissues, like a security guard that can’t tell residents from intruders. For investors, autoimmune diseases matter because they create long-term treatment needs, ongoing healthcare costs, and large markets for drugs, diagnostics, and devices; progress or setbacks in therapies, clinical trials, or approvals can strongly affect the value of companies working in this area.

peer-reviewed technical

"Excimer laser technology treatment procedures are supported by more than 300 published peer-reviewed clinical studies"

Peer-reviewed means a study, report or paper has been examined and approved by independent experts in the same field before publication, like having multiple qualified inspectors check a building plan. For investors, peer review signals that methods and conclusions have passed scrutiny beyond the author’s claims, making scientific, clinical or technical findings more reliable and reducing the chance that decisions or valuation are based on unchecked or flawed evidence.

FDA-cleared regulatory

"expanding access to targeted, FDA-cleared phototherapy in these prestigious centers"

FDA-cleared means a medical product—typically a device or diagnostic—has passed a U.S. regulator’s review showing it is substantially similar to an existing approved product and is safe and effective for its intended use. For investors, clearance acts like an official safety stamp that lowers regulatory risk and can speed market access, comparable to getting a trusted roadworthy certificate before selling cars, which can make sales and adoption happen faster.

AI-generated analysis. Not financial advice.

Latest STRATA customer strengthens academic leadership in XTRAC excimer laser treatment for psoriasis, vitiligo, and atopic dermatitis

HORSHAM, Pa., Feb. 18, 2026 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (Nasdaq: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative dermatologic treatments, today announces that Johns Hopkins Dermatology has added the XTRAC® 308 nm excimer laser to its clinical treatment offerings.

The addition of XTRAC enhances Johns Hopkins’ ability to deliver advanced, targeted care for patients living with chronic inflammatory and autoimmune skin diseases, including psoriasis, vitiligo, atopic dermatitis, and other complex dermatologic conditions. The technology will also support ongoing clinical research and academic initiatives within the department, reinforcing its commitment to evidence-based dermatologic innovation.

“Academic medical centers play a critical role in advancing evidence-based dermatologic care, an essential component to improving patient outcomes and quality of life,” said Dr. Dolev Rafaeli, Chief Executive Officer of STRATA Skin Sciences. “Collaboration with Johns Hopkins and other leading institutions that prioritize both clinical excellence and research innovation underscores the importance of precision treatment strategies in managing inflammatory skin disease while expanding access to targeted, FDA-cleared phototherapy in these prestigious centers.   STRATA Skin Sciences remains committed to partnering with top academic institutions worldwide to support research, education, and access to advanced dermatologic technologies.”

Johns Hopkins joins a distinguished group of leading academic institutions across the United States and internationally that have integrated XTRAC into their clinical programs. Centers such as New York University, University of California, Cleveland Clinic, Cornell University, and many others recognize the demonstrated effectiveness and patient-centered benefits of excimer laser therapy in managing challenging inflammatory skin conditions.

Excimer laser technology treatment procedures are supported by more than 300 published peer-reviewed clinical studies. Partnerships with renowned academic hospitals like Johns Hopkins further advance the generation of clinical evidence supporting precision phototherapy strategies.

About STRATA Skin Sciences, Inc.

STRATA Skin Sciences is a medical technology company dedicated to developing, commercializing, and marketing innovative products for the in-office treatment of various dermatologic conditions, such as psoriasis, vitiligo, and acne. Its products include the XTRAC^® excimer laser, VTRAC^® lamp systems, and the TheraClear^®X Acne Therapy System.

STRATA is proud to offer these exciting technologies in the U.S. through its unique Partnership Program. STRATA’s popular partnership approach includes a fee per treatment cost structure versus an equipment purchase, installation and use of the device, on-site training for practice personnel, service and maintenance of the equipment, dedicated account and customer service associates, and co-op advertising support to help raise awareness and promote the program within the practice.

Safe Harbor

This press release includes "forward-looking statements" within the meaning of the Securities Litigation Reform Act of 1995. These statements include but are not limited to the Company’s plans, objectives, expectations and intentions and may contain words such as “will,” “may,” “seeks,” and “expects,” that suggest future events or trends. More specific risks and uncertainties are set forth in the Company’s SEC reports on Forms 10-Q and 10-K. Given such uncertainties, any or all these forward-looking statements may prove to be incorrect or unreliable. The statements in this press release are made as of the date of this press release, even if subsequently made available by the Company on its website or otherwise. The Company does not undertake any obligation to update or revise these statements to reflect events or circumstances occurring after the date of this press release. The Company urges investors to carefully review its SEC disclosures available at www.sec.gov and www.strataskinsciences.com.

Investor Contact:
CORE IR
516-222-2560
IR@strataskin.com

FAQ

What did Johns Hopkins announce about adding XTRAC excimer laser on Feb 18, 2026 (SSKN)?

Johns Hopkins added the XTRAC 308 nm excimer laser to its clinical services on Feb 18, 2026. According to STRATA Skin Sciences, the device expands targeted treatment options for psoriasis, vitiligo, atopic dermatitis, and supports related clinical research and academic initiatives.

How does the XTRAC 308 nm excimer laser affect patient care at Johns Hopkins (SSKN)?

The XTRAC laser provides targeted phototherapy for localized inflammatory and autoimmune skin conditions. According to STRATA Skin Sciences, the technology enables precision treatment for psoriasis, vitiligo, and atopic dermatitis while supporting improved patient-centered care and research at Johns Hopkins.

Will the XTRAC addition at Johns Hopkins support clinical research and publications (SSKN)?

Yes, the XTRAC addition will support ongoing clinical research and academic initiatives at Johns Hopkins. According to STRATA Skin Sciences, the device reinforces evidence-based innovation and contributes to clinical studies and peer-reviewed research on precision phototherapy strategies.

Which conditions does Johns Hopkins plan to treat with XTRAC excimer laser (SSKN)?

Johns Hopkins plans to use XTRAC for psoriasis, vitiligo, atopic dermatitis, and other complex inflammatory skin diseases. According to STRATA Skin Sciences, the 308 nm excimer laser is FDA-cleared and widely used in academic centers for targeted phototherapy.

How does Johns Hopkins joining other institutions with XTRAC impact STRATA Skin Sciences (SSKN)?

Johns Hopkins joining peer institutions broadens academic adoption of XTRAC and may enhance clinical evidence generation. According to STRATA Skin Sciences, this collaboration aligns with other leading centers and supports expanded research, education, and access to targeted phototherapy.